...EV71 interaction in viral pathogenesis and the development of a mouse model expressing human SCARB2. Y's Therapeutics Co. Ltd.'s...

...plaque psoriasis. Another is YSPSL , a fusion protein of PSGL-1 and human IgG1 from Y's Therapeutics Co. Ltd....
...risk of seizure, he added, "with rigorous monitoring for adverse events like opportunistic infection." At Y's Therapeutics...
...Amsterdam, the Netherlands University of Verona , Verona, Italy Urigen Pharmaceuticals Inc. (OtcBB:URGP), Burlingame, Calif. Y's Therapeutics Co. Ltd....

...PSGL-1-targeted therapeutics to treat epilepsy. YSPSL, a recombinant fusion of PSGL-1 and human IgG1 from Y's Therapeutics Co. Ltd....

...John Wulf as EVP of business operations and CBO, formerly president, COO and CBO of Y's Therapeutics Co. Ltd. WIR...

...the trial will be presented in May at the American Transplant Congress in San Francisco. Y's Therapeutics Co. Ltd....

...Researchers from the University of Sao Paulo, Y's Therapeutics (Tokyo, Japan) and Northwestern University published in the...

...the product. Financial terms were not disclosed. Chromos Molecular Systems Inc . (TSX:CHR), Burnaby, B.C. Y's Therapeutics...

...recombinant molecule resulting from the fusion of P selectin glycoprotein ligand-1 (PSGL-1) and human IgG1. Y's Therapeutics...

...Incidence of delayed graft function (DGF) Status: Phase II started Milestone: Complete Phase II (2007) Y's Therapeutics...
...the trial will be open-label and dose-escalating, and the second will be double-blinded and placebo-controlled. Y's Therapeutics Co. Ltd....